Since the introduction of insulin almost a century ago, more than 80 peptide drugs have
reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis …

Understanding the in vivo transport of nanoparticles provides guidelines for designing
nanomedicines with higher efficacy and fewer side effects. Among many factors, the size of …

The blood-brain barrier (BBB) constitutes a microvascular network responsible for excluding
most drugs from the brain. Treatment of brain tumors is limited by the impermeability of the …

RNA interference mediated by small interfering RNAs (siRNAs) has been exploited for the
development of therapeutics. siRNAs can be a powerful therapeutic tool because the …

Neurological disorders such as Alzheimer's disease, stroke, and brain cancers are difficult to
treat with current drugs as their delivery efficacy to the brain is severely hampered by the …

Increasing attention has been paid to the diseases of central nervous system (CNS). The
penetration efficiency of most CNS drugs into the brain parenchyma is rather limited due to …

The blood–brain barrier (BBB) is a barrier that separates the blood from the brain tissue and
possesses unique characteristics that make the delivery of drugs to the brain a great …

Brain cancer, especially the most common type of glioblastoma, is highly invasive and
known as one of the most devastating and deadly neoplasms. Despite surgical and medical …

Therapies directed toward the central nervous system remain difficult to translate into
improved clinical outcomes. This is largely due to the blood–brain barrier (BBB), arguably …

Nanomedicine has emerged as a promising mean to improve theranostic efficacy and
reduce side effects. Currently, only very small percentage of injected dose reaches the solid …